



Date: \_\_\_\_\_

**Re:** \_\_\_\_\_

**DOB:** \_\_\_\_\_

**HSN:** \_\_\_\_\_

Dear \_\_\_\_\_:

I am writing to provide you with an update regarding the March 2016 notification that the above patient received a blood product that was implicated in the recent Canadian Blood Services (CBS) quarantine of blood products.

**Unit #:** \_\_\_\_\_

**Product:** \_\_\_\_\_

**Issued/Transfused:** \_\_\_\_\_

Canadian Blood Services have completed an exhaustive investigation and have found there were no anomalies identified with the implicated blood bags. After careful review of all investigations results, they have determined that all quarantined blood components associated with this event may now be released from quarantine and used for transfusion purposes. This concluded the investigation and has determined the blood products transfused were deemed to be safe for transfusion purposes.

Thank you for your clinical assistance and cooperation while we waited to hear the results of the CBS investigation of the suspected collection blood bags. Please contact either Dr. Donna Ledingham at 306-526-7576 (Regina and Southern Saskatchewan) or Dr. Sheila Harding at 306-655-1000 and request the physician on-call for Transfusions (Saskatoon and Northern Saskatchewan) if you have any further questions regarding the results of the investigation.

Sincerely,

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Contact Phone Number of Local Lab: \_\_\_\_\_